Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate calcium in tinnitus
IRCT2013121115751N1Phase 3Completed
- Sponsor
- Iran National Science Foundation
- Start
- May 2014
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of SNC-102 in tinnitus, sponsored by Iran National Science Foundation. Started May 2014; status: completed.
02
Drugs
SNC-102
03
Conditions
tinnitus
Beyond the preview
Go deeper on IRCT2013121115751N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013121115751N1.